Includes common stocks, ADRs and REITs listed on NYSE, Nasdaq or NYSE American with a prior day close of $2 a share or higher and volume of at least 50,000
Top Gainers/Price/Change/% Change
Aurora Acquisition Corp. (AURC) 31.59/21.21/204.34
Bullfrog AI Holdings Inc. (BFRG) 4.54/1.08/31.21
Kiniksa Pharmaceuticals Ltd. (KNSA) 19.88/4.94/33.07
Galecto Inc. (GLTO) 2.99/0.64/27.23
HHG Capital Corp. (HHGC) 12.31/1.72/16.24
Expert Commentary: Why These Stocks Rallied
Aurora Acquisition Corp.
AURC daily chart. Credit: Stocktwits
Self-driving technology firm, Aurora Innovation, announced its plans for a $600 million private placement of Class A common stock. Alongside this, Aurora Innovation has also kick-started an underwritten public offering for up to $200 million of its Class A common stock. In a regulatory filing, the company estimated its cash, cash equivalents and short-term investments to be around $785 million, excluding restricted cash, as of June 30. Furthermore, in November, it reported having over $1.2 billion in cash and short-term investments.
Bullfrog AI Holdings Inc.
BFRG daily chart. Credit: Stocktwits
BullFrog AI Holdings Inc., a pioneer in precision medicine utilizing artificial intelligence and machine learning for successful pharmaceutical and biologic development, has announced that the United States Patent and Trademark Office will issue US Patent No. 11,712,435 on August 1, 2023. This patent is set to safeguard the company’s innovative prodrugs derived from mebendazole, which are used in the treatment of various cancers and diseases.
Kiniksa Pharmaceuticals Ltd.
KNSA daily chart. Credit: Stocktwits
Kiniksa Pharmaceuticals has reported robust Q2 2023 results, with ARCALYST® (rilonacept). The net product revenue should reach $54.5 million. The company has raised its 2023 revenue guidance for ARCALYST to $220 – $230 million, indicating an approximately 84% year-over-year growth at the midpoint. Kiniksa is also anticipating Phase 2 rheumatoid arthritis data from KPL-404 in the first half of 2024. Furthermore, the company’s cash reserves are now projected to support operations until at least 2027. As the sole FDA-approved therapy for recurrent pericarditis, Kiniksa continues to demonstrate substantial progress in delivering ARCALYST to patients in need.
Galecto Inc.
GLTO daily chart. Credit: Stocktwits
No specific news was released for today for Galecto, Inc. But, last month the company announced its forthcoming inclusion in the Russell Microcap Index. Galecto, Inc. is a leading clinical-stage biotechnology company specializing in galectin biology and the development of innovative treatments for fibrosis and cancer. Shareholders supported the promising news of Galecto’s addition to the Russell Microcap Index, which not only validates its growth strategy but also enhances its visibility within the investment community, thus contributing to the 20% rise in stock.
HHG Capital Corp.
HHGC daily chart. Credit: Stocktwits
HHG Capital Corporation has made a significant announcement regarding a contribution to its trust account. The company revealed that on July 21, 2023, it deposited funds to extend the deadline to complete a business combination from July 23, 2023, to August 23, 2023. This strategic move involves a deposit of $0.0333 for each ordinary share issued during the initial public offering, for those shareholders who have not waived their rights to receive any part of any extension payment. Initiated on September 23, 2022, this extension is aimed at providing the company with ample time to finalize its plans and strategies.
The post Top Five Stock Market Gainers of 25/07/23: AURC, BFRG, KNSA, GLTO, HHGC appeared first on CoinChapter.
